NHD Global
Mitochondrial-derived peptide research · MOTS-c
Scientific Product Dossier
MOTS-c is a 16-amino-acid mitochondrial-derived peptide first described in 2015. The foundational paper linked cell effects with folate/purine metabolism and AMPK signaling and reported metabolic outcomes in mice. These were not human treatment results. FDA states that it has not identified human exposure data for drug products containing MOTS-c.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The discovery paper reported cell-signaling changes and protection against diet- and age-associated metabolic phenotypes in mice.
No controlled human administration or efficacy endpoint.
Read the primary studyFDA states it has not identified human exposure data for drug products containing MOTS-c.
The “Human” catalog qualifier denotes a sequence reference, not permission for human use.
Read the primary studyThe original study identified a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Cellular experiments linked its action to folate/purine metabolism and AMPK; mouse experiments addressed diet- and age-associated insulin resistance.
The discovery experiments do not establish benefit from administering MOTS-c to humans. The word Human in the catalog denotes the reference identity.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 40 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Lee C, et al. Cell Metabolism. 2015. PMID 25738459.
View primary recordU.S. FDA current MOTS-c summary.
View primary recordThird-party publications selected for direct relevance.
Lee C, et al. Cell Metabolism. 2015. PMID 25738453.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
It refers to the sequence context; it does not mean donor-derived, human-tested or intended for human use.
No. The foundational intervention findings came from cells and mice.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The paper that introduced MOTS-c combined cell experiments with mouse metabolic models. It is an important discovery record, but the intervention findings were preclinical.
Updated August 28, 2026
“Human” in a MOTS-c catalog title ordinarily describes the referenced peptide sequence; it does not mean the material was isolated from a human donor,…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: MS40 · 40 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
